VolitionRx’s (VNRX) Buy Rating Reiterated at D. Boral Capital

VolitionRx (NYSE:VNRX)‘s stock had its “buy” rating reiterated by stock analysts at D. Boral Capital in a report issued on Wednesday,Benzinga reports. They presently have a $5.00 price objective on the stock.

A number of other research analysts have also weighed in on VNRX. StockNews.com started coverage on VolitionRx in a report on Thursday, January 23rd. They issued a “sell” rating on the stock. Benchmark reissued a “hold” rating on shares of VolitionRx in a research note on Friday, November 22nd.

VolitionRx Price Performance

Shares of VolitionRx stock opened at $0.62 on Wednesday. The business has a 50 day simple moving average of $0.64 and a two-hundred day simple moving average of $0.66. The stock has a market capitalization of $57.18 million, a P/E ratio of -1.71 and a beta of 1.20. VolitionRx has a 12 month low of $0.43 and a 12 month high of $1.23.

Insiders Place Their Bets

In other news, Director Guy Archibald Innes bought 174,764 shares of the firm’s stock in a transaction on Monday, December 9th. The shares were bought at an average cost of $0.57 per share, for a total transaction of $99,615.48. Following the acquisition, the director now directly owns 617,085 shares of the company’s stock, valued at $351,738.45. This trade represents a 39.51 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Cameron John Reynolds purchased 139,811 shares of the company’s stock in a transaction dated Monday, December 9th. The stock was purchased at an average cost of $0.57 per share, with a total value of $79,692.27. Following the purchase, the chief executive officer now owns 2,117,404 shares in the company, valued at approximately $1,206,920.28. This trade represents a 7.07 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last 90 days, insiders have purchased 358,266 shares of company stock valued at $204,212. Insiders own 12.80% of the company’s stock.

Institutional Trading of VolitionRx

A hedge fund recently raised its stake in VolitionRx stock. Geode Capital Management LLC raised its position in shares of VolitionRx Limited (NYSE:VNRX) by 15.1% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 730,448 shares of the company’s stock after buying an additional 95,900 shares during the period. Geode Capital Management LLC owned about 0.79% of VolitionRx worth $439,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 8.09% of the company’s stock.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.